Universe Pharmaceuticals INC — FY2021 Form 20-F
Reporting period: Fiscal year ended September 30, 2021, compared with fiscal years 2020 and 2019. This is an annual report, not a standalone fourth-quarter filing; the filing does not provide clear Q4-only financial results. Financial amounts below are in U.S. dollars unless noted.
Business context
Universe is a Cayman Islands holding company whose operations are conducted through PRC subsidiaries. It manufactures traditional Chinese medicine derivative (TCMD) products and distributes pharmaceutical and medical products made by third parties. Its products are sold across 30 provinces in China. Self-manufactured products contributed 61.6% of FY2021 revenue; third-party products contributed 38.4%. The flagship Guben Yanling Pill represented 40.3% of total revenue.
Financial performance
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Revenue | $47.98 million | $30.70 million | +56.3% |
| Gross profit / margin | $25.33 million / 52.8% | $14.09 million / 45.9% | +79.7%; margin +6.9 percentage points |
| Operating income / margin | $13.59 million / 28.3% | $10.25 million / 33.4% | +32.6%; margin −5.1 percentage points |
| Net income / margin | $11.32 million / 23.6% | $7.56 million / 24.6% | +49.8%; margin −1.0 percentage point |
| Operating cash flow | $(2.06) million | $6.12 million | Turned negative |
| Cash at year-end | $8.08 million | $10.06 million | −$1.98 million |
| Short-term bank loans | $4.33 million | $2.65 million | +$1.69 million |
Revenue growth reflected recovery in customer numbers and TCMD sales volume, higher selling prices, and RMB appreciation, which management said positively affected reported revenue by about 7.1%. TCMD revenue rose 60.9% to $29.56 million; third-party product revenue rose 49.4% to $18.42 million. Management cited higher prices and a more favorable product mix as contributors to the gross-margin improvement. Operating expenses increased 205.5% to $11.74 million, led by R&D spending, advertising and public-company costs.
Liquidity, cash flow and capital commitments
At September 30, 2021, current assets were $50.48 million and current liabilities were $11.21 million, with reported working capital of $39.27 million. Current assets included $13.73 million of redeemable-at-discretion short-term wealth-management investments and $15.57 million of net receivables. The company reported that 75.4% of year-end net receivables had been collected by the report date. Operating cash flow was negative despite positive net income, principally reflecting growth in receivables, supplier advances and a $7.43 million advertising prepayment.
Net cash used in investing activities was $27.06 million, including $15.33 million of short-term investment purchases, $10.63 million of construction prepayments and $2.46 million of property prepayments. The March 2021 IPO raised approximately $25.6 million net. Remaining construction commitments for four manufacturing plants and an office building were approximately $14.83 million, including about $3.83 million due within 12 months. Management said available cash, operating cash flows, IPO proceeds and, if needed, bank borrowing should fund working-capital needs for the 12 months following issuance of the audited statements.
Material changes, outlook and unusual items
- After FY2020 revenue fell 7.6% amid COVID-19 disruption, FY2021 revenue rebounded 56.3%. The factory had closed briefly in February 2020 and resumed normal operations in March 2020; management described the FY2020–FY2021 impact as minimal overall but warned that a resurgence could disrupt sales, collections or supply.
- R&D expense increased 837.3% to $5.47 million, including spending to develop and test eight new products. Management plans to expand product development, brand promotion and distribution; it provided no quantified financial guidance.
- The company prepaid $7.49 million for a one-year television advertising campaign. The prepayment was expensed when the advertisement first aired in October 2021. Management cautioned that advertising may not produce returns sufficient to cover its cost.
- The company prepaid $10.71 million toward a construction project with a budget of up to approximately $25.5 million, expected to be completed by August 2023. It also prepaid $2.48 million toward a $4.95 million property purchase from an entity in which the CEO then held a 5% interest. The filing says the material transactions were not submitted for board or committee approval; the company said it intended to obtain board approval for future material transactions.
- In December 2021, after year-end, the company agreed to build a manufacturing and R&D facility with Japanese pharmaceutical company Kitanihon, at Universe’s cost, and to purchase approximately $1.56 million of Kitanihon shares. Separately, the controlling shareholder agreed to transfer Sununion shares valued at $2.5 million to Kitanihon in connection with rights to use certain intellectual property; the transfer was reported as in progress.
- Management identified a material weakness in financial reporting controls: the internal audit function was not properly established. Disclosure controls were deemed ineffective as of September 30, 2021. Remediation plans include hiring qualified internal-audit personnel, establishing an audit plan and potentially engaging outside support; remediation was not confirmed complete.
- The company reported no material litigation. It disclosed past shortfalls in employee social-insurance and housing-fund contributions before April 2020, with potential exposure to required catch-up payments and charges. It does not carry product-liability or business-interruption insurance.
Key investor verification points
- Confirm the sustainability of FY2021 revenue growth and gross-margin gains, including the effects of higher selling prices, product mix and currency translation.
- Assess the quality and collection of receivables, the recoverability of supplier advances and the liquidity and risk profile of wealth-management investments.
- Track operating cash conversion, construction spending, remaining project funding needs and the company’s ability to meet near-term loan maturities.
- Verify that the television advertising campaign and capacity expansion deliver measurable returns, and monitor costs, delays and approvals.
- Review remediation of the disclosed material weakness and governance processes for material and related-party transactions.
- Monitor PRC regulatory and cross-border cash-transfer risks, tax incentives, and the implications of the post-year-end Kitanihon agreements.